Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on October 26, 2021, at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.

The webinar will feature presentations by KOLs Richard J. Glassock, MD, MACP, FRCP, FASN (David Geffen School of Medicine at UCLA), and Peter Browett, BMedSci, MBChB, FRACP, FRCPA (University of Auckland School of Medicine). They will discuss the current treatment landscape and unmet medical need in treating patients with complement mediated renal and hematological diseases.

Arrowhead’s management team will discuss the biology of the target, preclinical data generated to date, and clinical plans for ARO-C3. ARO-C3 is designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. Arrowhead recently nominated ARO-C3 as a clinical candidate and intends to file a CTA in the fourth quarter of 2021 to begin clinical studies.

The webinar may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website on October 26, and a replay will be made available following the conclusion of the webinar.

Richard J. Glassock, MD, MACP, FRCP, FASN graduated from the UCLA School of Medicine in 1960 and received post-graduate training at UCLA, Harvard and Scripps Research Institute. His main interests are in glomerular disease, chronic kidney disease and clinical nephrology. He has published over 750 original papers, books, book chapters and reviews. He is the past-president of the American Society of Nephrology, the National Kidney Foundation (USA), and past-Chairman of the American Board of Internal Medicine. He is the former Chair of the Departments of Medicine at the University of Kentucky (1992-1999) and Harbor-UCLA Medical Center (1980-1992). He is a Master of The American College of Physicians and a Fellow of The Royal College of Physicians (UK).

Dr. Glassock was the founding Editor-in-Chief of the NephSAP Journal of the American Society of Nephrology (2002). He is an Editor of the Nephrology section of UpToDate, an Associate Editor of the American Journal of Nephrology and a founding Moderator of The ASN Communities on-line site. He has received the David Hume Memorial Award of the National Kidney Foundation, The Robert Narins Award of the American Society of Nephrology, Distinguished Achievement Awards from UCLA and the Association of Professors of Medicine, The Torchbearer Award of the American Kidney Fund, and the Medal of Excellence Award from the American Association of Kidney Patients (in 2014). He is currently Professor Emeritus at the David Geffen School of Medicine at UCLA and an independent medical consultant.

Peter Browett, BMedSci, MBChB, FRACP, FRCPA, is a consultant haematologist at Auckland City Hospital and Professor of Pathology in the Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland. He is a graduate of the University of Otago Medical School, and after postgraduate training in clinical and laboratory haematology in Auckland, he was a Wellcome – HRC research fellow in the Department of Haematology, Royal Free Hospital School of Medicine, London. Dr. Browett is involved in several co-operative group and investigator-initiated studies in blood disorders and stem cell transplantation. He is co-director of the Leukaemia and Blood Cancer Research Unit, with interests in blood cancer genomics, biomarkers in leukaemia, and the monitoring of measurable residual disease. Dr. Browett is Clinical Director of the Auckland Regional Biobank, and Grafton Clinical Genomics.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the continuing impact of the COVID-19 pandemic, the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006093/en/